Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728

*You need to join by phone if you want to ask Dr. Stein your questions.*

IDH mutations are found in approximately 20% of adults with AML. Both IDH1 and IDH2 mutations are typically found in older AML patients and have an intermediate risk profile, with IDH2 being the more common of the two. Targeted therapy drugs, called IDH inhibitors have been developed to address these mutations.

Ivosidenib (Tibsovo) and enasidinib (Idhifa) are IDH inhibitors and were approved for use in relapsed/refractory AML with IDH1 and IDH2 mutations, respectively. Clinical trials have been exploring the use of different combinations with other drugs such as azacitidine and venetoclax to improve their effectiveness. 

Ivosidenib (Tibsovo) was just recently approved by the FDA in May 2022 for use in combination with azacitidine for newly diagnosed patients age 75 years or older and those not able to do intensive chemotherapy.

In this podcast episode, Dr. Eytan Stein will discuss IDH mutations, the current treatment options, as well as the recent FDA approval of ivosidenib (Tibsovo) and what that means for today's treament landscape.

Thank you to our episode sponsor, Bristol Myers Squibb.

IDH mutations are found in approximately 20% of adults with AML. Both IDH1 and IDH2 mutations are typically found in older AML patients and have an intermediate risk profile, with IDH2 being the more common of the two. Targeted therapy drugs, called IDH inhibitors have been developed to address these mutations.

Ivosidenib (Tibsovo) and enasidinib (Idhifa) are IDH inhibitors and were approved for use in relapsed/refractory AML with IDH1 and IDH2 mutations, respectively. Clinical trials have been exploring the use of different combinations with other drugs such as azacitidine and venetoclax to improve their effectiveness. 

In this show, we were joined by Dr. Eytan Stein, an AML expert from Memorial Sloan Kettering Cancer Center, who summarized the IDH1 and IDH2 mutations and the current treatment options available. Dr. Stein covered the use of ivosidenib (Tibsovo) to treat IDH1 mutations and the use of enasidnib (Idhifa) to treat IDH2 mutations. He also addressed the recent FDA approval of the ivosidenib (Tibsovo) combination with azacitidine and how that will affect the treatment of IDH1-mutated AML.

Thank you to our episode sponsor, Bristol Myers Squibb.